The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review

References

• Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21(4):245. doi:10.1038/S41577-021-00522-1.
   PubMed Web of Science ®Google Scholar
• Wang F, Qu M, Zhou X, Zhao K, Lai C, Tang Q, Xian W, Chen R, Li X, Li Z, et al. The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China. J Transl Med. 2020;18(1):270. doi:10.1186/S12967-020-02423-8.
   PubMed Web of Science ®Google Scholar
• Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100. doi:10.1016/J.IT.2020.10.004.
   PubMed Web of Science ®Google Scholar
• Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P, Cao J-M. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol. 2020;10. doi:10.3389/fcimb.2020.587269.
   Web of Science ®Google Scholar
• Cosar B, Karagulleoglu ZY, Unal S, Ince AT, Uncuoglu DB, Tuncer G, Kilinc BR, Ozkan YE, Ozkoc HC, Demir IN, et al. SARS-CoV-2 mutations and their viral variants. Cytokine Growth Factor Rev. 2022;63(2):10. doi:10.1016/J.CYTOGFR.2021.06.001.
   PubMedGoogle Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet (London, England). 2021;398(10317):2126. doi:10.1016/S0140-6736(21)02758-6.
   PubMed Web of Science ®Google Scholar
• Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. doi:10.1002/RMV.2381.
   PubMed Web of Science ®Google Scholar
• Araf Y, Akter F, Dong TY, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825. doi:10.1002/JMV.27588.
   PubMed Web of Science ®Google Scholar
• Shishir TA, Jannat T, Bin Naser I. An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant. PLoS One. 2022;17(4):e0266844. doi:10.1371/JOURNAL.PONE.0266844.
   PubMed Web of Science ®Google Scholar
• Divino F, Alaimo Di Loro P, Farcomeni A, Jona-Lasinio G, Lovison G, Ciccozzi M, Mingione M, Maruotti A. Decreased severity of the Omicron variant of concern: further evidence from Italy. Int J Infect Dis. 2022;119:21. doi:10.1016/J.IJID.2022.03.023.
   PubMed Web of Science ®Google Scholar
• Rzymski P, Szuster-Ciesielska A. The COVID-19 vaccination still matters: Omicron variant is a final wake-up call for the rich to help the poor. Vaccines. 2022;10(7):1070. doi:10.3390/VACCINES10071070.
   Web of Science ®Google Scholar
• Qin C, Yan W, Tao L, Liu M, Liu J. The association between risk perception and hesitancy toward the booster dose of COVID-19 vaccine among people aged 60 years and older in China. Vaccines. 2022;10(7):1112. doi:10.3390/vaccines10071112.
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/JOURNAL.PMED.1000097.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Kremer C, Braeye T, Proesmans K, André E, Torneri A, Hens N. Observed serial intervals of SARS-CoV-2 for the Omicron and Delta variants in Belgium based on contact tracing data, 19 November to 31 December 2021. medRxiv. Published online 2022 Jan 30. doi:10.1101/2022.01.28.22269756.
   Google Scholar
• Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Møller CH, Skov RL, Krause TG, Rasmussen M, Sieber RN, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from Danish Households. medRxiv. Published online 2022 Jan 30. doi:10.1101/2022.01.28.22270044.
   Google Scholar
• Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, Bruxvoort KJ, Tubert JE, Florea A, Ku JH, et al. Effectiveness of Mrna-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063–23. doi:10.1038/s41591-022-01753-y.
   PubMed Web of Science ®Google Scholar
• Ulloa AC, Buchan SA, Daneman N, Brown KA. Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv. Published online 2022 Jan 2. doi:10.1101/2021.12.24.21268382.
   Google Scholar
• Vieillard-Baron A, Flicoteaux R, Salmona M, Annane D, Ayed S, Azoulay E, Bellaiche R, Beloucif S, Berti E, Bertier A, et al. Epidemiological characteristics and severity of Omicron variant cases in the APHP critical care units. medRxiv. Published online 2022 Jan 28. doi:10.1101/2022.01.25.22269839.
   Google Scholar
• Veneti L, Bøås H, Kristoffersen AB, Stålcrantz J, Bragstad K, Hungnes O, Storm ML, Aasand N, Rø G, Starrfelt J, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill. 2022;27(4). doi:10.2807/1560-7917.ES.2022.27.4.2200077.
   PubMedGoogle Scholar
• Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, Khunti K, Hippisley-Cox J, Banerjee A, Walker AS, et al. Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2). medRxiv. Published online 2022 Feb 25. doi:10.1101/2022.02.24.22271466.
   Google Scholar
• Wolter N, Jassat W, von Gottberg A, Cohen C. Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa. Lancet (London, England). 2022;400(10346):93–6. doi:10.1016/S0140-6736(22)00981-3.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet (London, England). 2022;399(10323):437–46. doi:10.1016/S0140-6736(22)00017-4.
   PubMed Web of Science ®Google Scholar
• Spensley KJ, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, Thomas D, McAdoo SP, Randell P, Kelleher P, et al. Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in hemodialysis patients. Kidney Int Rep. 2022;7(6):1406–9. doi:10.1016/j.ekir.2022.04.005.
   PubMed Web of Science ®Google Scholar
• de Souza, UJB, Dos Santos RN, de Melo FL, de Souza UJB, de Melo FL, Belmok A, Galvão JD, de Rezende TCV, Cardoso FDP, Carvalho RF, et al. Genomic epidemiology of SARS-CoV-2 in Tocantins State and the diffusion of P.1.7 and AY.99.2 lineages in Brazil. Viruses. 2022;14(4):659. doi:10.3390/V14040659/S1.
   PubMed Web of Science ®Google Scholar
• Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, Manyane T, Komane L, Venter M, Jassat W, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. Lancet Child Adolesc Heal. 2022;6(5):294–302. doi:10.1016/S2352-4642(22)00027-X.
   Web of Science ®Google Scholar
• Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CB, et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022;27(4). doi:10.2807/1560-7917.ES.2022.27.4.2101196.
   Google Scholar
• Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J, Tang D, Walters CE, et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science. 2022;375(6587):1406–11. doi:10.1126/SCIENCE.ABN8347/SUPPL_FILE/SCIENCE.ABN8347_SM.PDF.
   PubMed Web of Science ®Google Scholar
• Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC, Rasmussen M, Madsen SL, Espersen CH, Sieber RN, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Eurosurveillance. 2021;26(50):2101146. doi:10.2807/1560-7917.ES.2021.26.50.2101146/CITE/PLAINTEXT.
   Web of Science ®Google Scholar
• Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston DC, Forman M, Abdullah O, Gallagher N, Li M, et al. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads. medRxiv. Published online 2022 Jan 28. doi:10.1101/2022.01.26.22269927.
   Google Scholar
• Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–63. doi:10.15585/MMWR.MM7107E2.
   PubMed Web of Science ®Google Scholar
• Garg R, Gautam P, Suroliya V, Agarwal R, Bhugra A, Kaur US, Das S, Bihari C, Agarwal A, Sarin SK, et al. Evidence of early community transmission of Omicron (B1.1.529) in Delhi- a city with very high seropositivity and past-exposure. Travel Med Infect Dis. 2022;46:102276. doi:10.1016/J.TMAID.2022.102276.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639–51. doi:10.1001/JAMA.2022.0470.
   PubMed Web of Science ®Google Scholar
• Allen H, Tessier E, Turner C, Anderson C, Blomquist P, Simons D, Løchen A, Jarvis CI, Groves N, Capelastegui F, et al. Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England. medRxiv. Published online 2022 Feb 17. doi:10.1101/2022.02.15.22271001.
   Google Scholar
• Andeweg SP, de Gier B, Eggink D, van den Ende C, van Maarseveen N, Ali L, Vlaemynck B, Schepers R, Hahné SJ, Reusken CB, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. medRxiv. Published online 2022 May 12. doi:10.1101/2022.02.06.22270457.
   Google Scholar
• Auvigne V, Vaux S, Strat YL, Schaeffer J, Fournier L, Tamandjou C, Montagnat C, Coignard B, Levy-Bruhl D, Parent du Châtelet I. Severe hospital events following symptomatic infection with SARS-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: a retrospective, population-based, matched cohort study. eClinicalmedicine. 2022;48:48. doi:10.1016/j.eclinm.2022.101455.
   Google Scholar
• Boucau J, Marino C, Regan J, Uddin RChoudhary MC, Flynn JP, Chen G, Stuckwisch AM, Mathews J, Liew MY, et al. Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. medRxiv. 2022;3. doi:10.1101/2022.03.01.22271582.
   Google Scholar
• Cedro-Tanda A, Gómez-Romero L, de Anda-Jauregui G, Garnica-López D, Alfaro-Mora Y, Sánchez-Xochipa S, García-García EF, Mendoza-Vargas A, Frías-Jiménez EJ, Moreno B, et al. Early genomic, epidemiological, and clinical description of the SARS-CoV-2 Omicron variant in Mexico City. medRxiv. Published online 2022 Feb 7. doi:10.1101/2022.02.06.22270482.
   Google Scholar
• Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F, Young HP, Breban MI, Billig K, Koch RT, et al. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med. 2022;3(5):325–34.e4. doi:10.1016/j.medj.2022.03.010.
   PubMedGoogle Scholar
• Christensen PA, Olsen RJ, Long SW, Snehal R, Davis JJ, Ojeda Saavedra M, Reppond K, Shyer MN, Cambric J, Gadd R, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 caused by the Omicron variant of severe acute respiratory syndrome Coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192(4):642–52. doi:10.1016/j.ajpath.2022.01.007.
   PubMed Web of Science ®Google Scholar
• SARS-CoV-2 variants of concern and variants under investigation in England.
   Google Scholar
• Petros BA, Turcinovic J, Welch NL, White LF, Kolaczyk ED, Bauer MR, Cleary M, Dobbins ST, Doucette-Stamm L, Gore M, et al. Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations. Clin Infect Dis. Published online 2022 May 25. doi:10.1093/CID/CIAC413.
   Web of Science ®Google Scholar
• Rathinasamy M, Kandhasamy S. An exploratory study on the propagation of SARS-CoV-2 variants: Omicron is the most predominant variant. J Med Virol. 2022;94(6):2414–21. doi:10.1002/JMV.27634.
   PubMed Web of Science ®Google Scholar
• Rufino J, Baquero C, Frey D, Glorioso CA, Ortega A, Reščič N, Roberts JC, Lillo RE, Menezes R, Champati JP, et al. Using survey data to estimate the impact of the Omicron variant on vaccine efficacy against COVID-19 infection. medRxiv. Published online 2022 Jan 21. doi:10.1101/2022.01.21.22269636.
   Google Scholar
• Sharma RP, Gautam S, Sharma P, Singh R, Sharma H, Parsoya D, Deba F, Bhomia N, Pal N, Potdar VA, et al. Clinico epidemiological profile of Omicron variant of SARS CoV2 in Rajasthan. medRxiv. Published online 2022 Feb 13. doi:10.1101/2022.02.11.22270698.
   Google Scholar
• Smallman-Raynor MR, Cliff AD. Consortium TC-19 GU (COG-U. Spatial growth rate of emerging SARS-CoV-2 lineages in England, September 2020–December 2021. Epidemiol Infect. 2022;150:e145. doi:10.1017/S0950268822001285.
   PubMed Web of Science ®Google Scholar
• Lambrou A, Shirk P, Steele M, Paul P, Paden CR, Cadwell B, Reese HE, Aoki Y, Hassell N, Zheng X-Y, et al. Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants — United States, June 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(6):206–11. doi:10.15585/MMWR.MM7106A4.
   PubMedGoogle Scholar
• Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November−December 2021. J Med Virol. 2022;94(5):2290–5. doi:10.1002/JMV.27613.
   PubMed Web of Science ®Google Scholar
• Jalali N, Brustad HK, Frigessi A, MacDonald E, Meijerink H, Feruglio S, Nygård K, Rø GI, Madslien EH, De Blasio BF. Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. medRxiv. Published online 2022 Feb 18. doi:10.1101/2022.02.07.22270437.
   Google Scholar
• Ouafi M, Dubos F, Engelman I, Lazrek M, Guigon A, Bocket L, Hober D, Alidjinou EK. Rapid syndromic testing for respiratory viral infections in children attending the emergency department during COVID-19 pandemic in Lille, France, 2021–2022. J Clin Virol. 2022;153:105221. doi:10.1016/J.JCV.2022.105221.
   PubMed Web of Science ®Google Scholar
• Chen LL, Abdullah SMU, Chan WM, Chan BPC, Ip JD, Chu AWH, Lu L, Zhang X, Zhao Y, Chuang VWM, et al. Contribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong. Nat Commun. 2022;13(1):1–0. doi:10.1038/s41467-022-31395-0.
   PubMed Web of Science ®Google Scholar
• Haan TJ, Smith LK, DeRonde S, House E, Zidek J, Puhak D, Mullen L, Redlinger M, Parker J, Barnes BM, et al. A repeat pattern of founder events for SARS-CoV-2 variants in Alaska. medRxiv. Published online 2022 May 26. doi:10.1101/2022.05.25.22275610.
   Google Scholar
• Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing incidence of chemosensory changes by COVID-19 variant. Otolaryngol Head Neck Surg. 2023;168(4):704–6. Published online 2022 May 3. doi:10.1177/01945998221097656.
   PubMed Web of Science ®Google Scholar
• Wattiaux AL, May F, Allen T, Bladen T, Pery B, McHugh L, Slinko V, Sykes A, De Silva L, Bajra J, et al. Communicable diseases intelligence 2022 - Defining the peak - Point prevalence of SARS-CoV-2 using randomised sampling. Commun Dis Intell. 2022;46. Published online 2022. doi:10.33321/cdi.2022.46.24.
   Web of Science ®Google Scholar
• Novazzi F, Baj A, Genoni A, Focosi D, Maggi F. Expansion of L452R-Positive SARS-CoV-2 Omicron variant, Northern Lombardy, Italy - Volume 28, number 6—June 2022 - Emerging infectious diseases journal - CDC. Emerg Infect Dis. 2022;28(6):1301–2. doi:10.3201/EID2806.220210.
   PubMed Web of Science ®Google Scholar
• Carrazco-Montalvo A, Herrera-Yela A, Alarcón-Vallejo D, Gutiérrez-Pallo D, Armendáriz-Castillo I, Andrade-Molina D, Muñoz-Mawyin K, Fernández-Cadena JC, Morey-León G, Patiño L. Omicron sub-lineages (BA.1.1.529 + BA.*) current status in Ecuador. Viruses. 2022;14(6):1177. doi:10.3390/V14061177.
   PubMed Web of Science ®Google Scholar
• Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US. medRxiv. Published online 2022 Feb 22. doi:10.1101/2022.02.21.22271300.
   Google Scholar
• Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv. Published online 2022 Jan 2. doi:10.1101/2021.12.30.21268495.
   Google Scholar
• Boscolo-Rizzo P, Tirelli G, Meloni P, Hopkins C, Madeddu G, De Vito A, Gardenal N, Valentinotti R, Tofanelli M, Borsetto D, et al. Coronavirus disease 2019 (COVID-19)–related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) Omicron variant. Int Forum Allergy Rhinol. 2022;12(10):1273–81. Published online 2022. doi:10.1002/ALR.22995.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi C, Henry BM, Lippi G. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel? Int J Infect Dis. 2022;118:167–8. doi:10.1016/J.IJID.2022.03.008.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome MJ, Amoako DG, Everatt J, Bhiman JN, Scheepers C, et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun. 2022;13(1):1–8. doi:10.1038/s41467-022-33614-0.
   PubMed Web of Science ®Google Scholar
• Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, Talbot HK, Casey JD, Zepeski A, Shapiro NI, et al. Vaccine effectiveness of primary series and booster doses against COVID-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022:379. doi:10.1136/BMJ-2022-072065.
   Google Scholar
• Bal A, Simon B, Destras G, Chalvignac R, Semanas Q, Oblette A, Quéromès G, Fanget R, Regue H, Morfin F, et al. Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circu-lation in France. doi:10.1038/s41467-022-33910-9.
   Google Scholar
• Bezerra MF, Silva LCA, Pessoa-e-Silva R, Soares GL, Dezordi FZ, Lima GB, Lima RE, Campos TL, Docena C, Oliveira AB, et al. Real-life evaluation of a rapid antigen test (DPP SARS-CoV-2 antigen) for COVID-19 diagnosis of primary healthcare patients, in the context of the Omicron-dominant wave in Brazil. Clin Microbiol Infect. 2022;29(3):e392.1–5. doi:10.1016/j.cmi.2022.11.003.
   Web of Science ®Google Scholar
• Chadeau-Hyam M, Tang D, Eales O, Bodinier B, Wang H, Jonnerby J, Whitaker M, Elliott J, Haw D, Walters CE, et al. Omicron SARS-CoV-2 epidemic in England during February 2022: a series of cross-sectional community surveys. Lancet Reg Health Eur. 2022;21:100462. doi:10.1016/J.LANEPE.2022.100462.
   PubMedGoogle Scholar
• Eales O, De Oliveira Martins L, Page AJ, Wang H, Bodinier B, Tang D, Haw D, Jonnerby J, Atchison C, Ashby D, et al. Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-32096-4.
   Web of Science ®Google Scholar
• Elliott P, Eales O, Bodinier B, Tang D, Wang H, Jonnerby J, Haw D, Elliott J, Whitaker M, Walters CE, et al. Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-32121-6.
   Web of Science ®Google Scholar
• Elliott P, Eales O, Steyn N, Tang D, Bodinier B, Wang H, Elliott J, Whitaker M, Atchison C, Diggle PJ, et al. Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. Science. 2022;376(6600). doi:10.1126/science.abq4411.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhao X, Chen Z, Nie K, Yin Z, Xia Y, Wang J, Niu P, A R, Li L, et al. Genomic surveillance for SARS-CoV-2 variants of concern from imported COVID-19 cases - the Mainland of China, 2021. China CDC Wkly. 2022;4(31):680–4. doi:10.46234/CCDCW2022.144.
   PubMedGoogle Scholar
• Francesconi M, Giovanetti M, De Florio L, Fogolari M, Veralli R, De Flora C, Spoto S, Maruotti A, Riva E, Angeletti S, et al. Genomic epidemiology unveil the Omicron transmission dynamics. Pathogens. 2022;11(9):1011. Published online 2022. doi:10.3390/pathogens11091011.
   PubMed Web of Science ®Google Scholar
• Gladkikh A, Dedkov V, Sharova A, Klyuchnikova E, Sbarzaglia V, Kanaeva O, Arbuzova T, Tsyganova N, Popova A, Ramsay E, et al. Epidemiological features of COVID-19 in Northwest Russia in 2021. Viruses. 2022;14(5):931. doi:10.3390/V14050931.
   PubMed Web of Science ®Google Scholar
• Lai E, Kennedy EB, Lozach J, Hayashibara K, Davis-Turak J, Becker D, Brzoska P, Cassens T, Diamond E, Gandhi M, et al. A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, and early detection of emergent variants such as Omicron. J Clin Microbiol. 2022;60(7). doi:10.1128/JCM.00342-22/ASSET/90D1ABC2-F7BE-4B05-B250-E784DE567A41/ASSETS/IMAGES/LARGE/JCM.00342-22-F003.JPG.
   PubMed Web of Science ®Google Scholar
• Loconsole D, Centrone F, Sallustio A, Accogli M, Casulli D, Sacco D, Zagaria R, Morcavallo C, Chironna M. Characteristics of the first 284 patients infected with the SARS-CoV-2 Omicron BA.2 subvariant at a single center in the Apulia Region of Italy, January–March 2022. Vaccines. 2022;10(5):674. doi:10.3390/VACCINES10050674.
   Web of Science ®Google Scholar
• Mattiuzzi C, Henry BM, Lippi G. Regional association between mean air temperature and case numbers of multiple SARS-CoV-2 lineages throughout the pandemic. Viruses. 2022;14(9):1913. doi:10.3390/V14091913.
   PubMed Web of Science ®Google Scholar
• Mella-Torres A, Escobar A, Barrera-Avalos C, Vargas-Salas S, Pirazzoli M, Gonzalez U, Valdes D, Rojas P, Luraschi R, Vallejos-Vidal E, et al. Epidemiological characteristics of Omicron and Delta SARS-CoV-2 variant infection in Santiago, Chile. Front Public Heal. 2022;10:3590. doi:10.3389/FPUBH.2022.984433/BIBTEX.
   Web of Science ®Google Scholar
• Menasria T, Aguilera M. Genomic diversity of SARS-CoV-2 in Algeria and North African Countries: what we know so far and what we expect? Microorganisms. 2022;10(2):467. doi:10.3390/microorganisms10020467.
   PubMed Web of Science ®Google Scholar
• Phan T, Boes S, McCullough M, Gribschaw J, Marsh JW, Harrison LH, Wells A. First detection of SARS-CoV-2 Omicron BA.4 variant in Western Pennsylvania, United States. J Med Virol. 2022;94(9):4053–5. doi:10.1002/JMV.27846.
   PubMed Web of Science ®Google Scholar
• Phan T, Boes S, McCullough M, Gribschaw J, Marsh JW, Harrison LH, Wells A. Emergence of SARS-CoV-2 Omicron BA.5 variant of concern in Western Pennsylvania, United States. J Med Virol. 2022;94(10):4593–4. doi:10.1002/JMV.27945.
   PubMed Web of Science ®Google Scholar
• Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CDFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat Commun. 2022;13(1):1–0. doi:10.1038/s41467-022-33169-0.
   PubMed Web of Science ®Google Scholar
• Singh SP, Tandel K, Kalra DK, Babu B, Thosani P, Anand KB. Prevalence of Omicron variant during the third wave of COVID-19 at a tertiary care hospital in Western Maharashtra. Med J Armed Forces India. Published online 2022 Oct 20. doi:10.1016/J.MJAFI.2022.08.009.
   Google Scholar
• Stefanelli P, Trentini F, Petrone D, Mammone A, Ambrosio L, Manica M, Guzzetta G, d’Andrea V, Marziano V, Zardini A, et al. Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. Eurosurveillance. 2022;27(45):2200125. doi:10.2807/1560-7917.ES.2022.27.45.2200125/CITE/PLAINTEXT.
   Web of Science ®Google Scholar
• Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, Matsubayashi K, Hattori S, Taniguchi C. Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. Int J Environ Res Public Heal. 2022;19(10):6330. doi:10.3390/IJERPH19106330.
   PubMed Web of Science ®Google Scholar
• Tang CY, Boftsi M, Staudt L, McElroy JA, Li T, Duong S, Ohler A, Ritter D, Hammer R, Hang J, et al. SARS-CoV-2 and influenza co-infection: a cross-sectional study in central Missouri during the 2021–2022 influenza season. Virology. 2022;576:105–10. doi:10.1016/J.VIROL.2022.09.009.
   PubMed Web of Science ®Google Scholar
• Tsao J, Kussman AL, Costales C, Pinsky BA, Abrams GD, Hwang CE. Accuracy of rapid antigen vs reverse transcriptase–polymerase chain reaction testing for SARS-CoV-2 infection in college athletes during prevalence of the Omicron variant. JAMA Netw Open. 2022;5(6):e2217234. doi:10.1001/JAMANETWORKOPEN.2022.17234.
   PubMed Web of Science ®Google Scholar
• Whitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, Donnelly CA, Chadeau-Hyam M, Elliott P. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun. 2022;13(1):1–10. doi:10.1038/s41467-022-34244-2.
   PubMed Web of Science ®Google Scholar
• Zaman K, Shete AM, Mishra SK, Kumar A, Reddy MM, Sahay RR, Yadav S, Majumdar T, Pandey AK, Dwivedi GR, et al. Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India. Front Med. 2022;9:3142. doi:10.3389/FMED.2022.955930/BIBTEX.
   Web of Science ®Google Scholar
• Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y, et al. Sub-lineages of the SARS-CoV-2 Omicron variants: characteristics and prevention. MedComm. 2022;3(3). doi:10.1002/MCO2.172.
   Google Scholar
• Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, Nasreen S, Schwartz KL, Sundaram ME, Tadrous M, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5(9):e2232760. doi:10.1001/jamanetworkopen.2022.32760.
   PubMed Web of Science ®Google Scholar
• Arabi M, Al-Najjar Y, Mhaimeed N, Salameh MA, Paul P, Al Anni J, Abdelati AA, Laswi I, Khanjar B, Al-Ali D, Elshafeey A, Mhaimeed O, Burney Z, D’Souza A, Sinha P, Bhatti M, Pillai KV, Homssi M, Bshesh K, Yagan L, Zakaria D. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: a systematic review. J Cell Mol Med. 2023;00:1–22. doi:10.1111/jcmm.17747.
   Google Scholar
• Lau JJ, Cheng SMS, Leung K, Lee CK, Hachim A, Tsang LCH, Yam KWH, Chaothai S, Kwan KKH, Chai ZYH, et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023;29(2):348–57. doi:10.1038/s41591-023-02219-5.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhang Y, Wang F, Wu D, Qian Z-H, Zhang R, Wang A-B, Huang C, Wang H, Ye Y, et al. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. BMJ Open. 2022;12(11):e063919. doi:10.1136/bmjopen-2022-063919.
   PubMed Web of Science ®Google Scholar
• Paul P, El-Naas A, Hamad O, Salameh MA, Mhaimeed N, Laswi I, Abdelati AA, AlAnni J, Khanjar B, Al-Ali D, et al. Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity and mortality compared to Delta and other variants: a systematic review. Hum Vaccines Immunother. 2023;19(1). doi:10.1080/21645515.2023.2167410.
   PubMed Web of Science ®Google Scholar
• CDC recommends the first updated COVID-19 booster | CDC online newsroom | CDC. [accessed 2022 Oct 12]. https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html.
   Google Scholar
• Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent omicron-containing booster vaccine against covid-19. N Engl J Med. 2022;387(14):1279–91. doi:10.1101/2022.06.24.22276703.
   PubMed Web of Science ®Google Scholar
• Wang CY, Hwang K-P, Kuo H-K, Kuo B-S, Liu H, Hou K-L, Tsai W-Y, Chiu H-C, Ho Y-H, Cheng J, et al. UB-612, a multitope universal vaccine eliciting a balanced B and T cell immunity against SARS-COV-2 variants of concern. J Clin Invest. 2022;132(10). doi:10.1101/2022.04.11.22272364.
   Google Scholar